Oxderys (doxorubicin hydrochloride)

Where it stands

Oxderys (doxorubicin hydrochloride), from Avyxa Holdings, is recorded as approved in the US. The FDA approval is dated 2026-11-09 under NDA221093. The official milestone describes it as a new formulation or manufacturer, supplied as a vial.

The records leave several fields blank: the therapeutic area, the approved indication, and the CHMP opinion date. They do not say what Oxderys is approved to treat, who may receive it, or at what dose. They also do not say whether it is a conventional or a liposomal presentation. Any statement on labelled use would need the approved prescribing information.

Regulatory pathway and designations

The only designation recorded is 'New formulation or manufacturer'. This is an FDA approval category. It generally means the product is not a new molecular entity but differs from an already-marketed product in formulation or in who makes it. The records do not say which of the two applies to Oxderys, or which reference product it relates to.

The records do not state the application type, for example whether it was filed under section 505(b)(2). They also do not mention priority review, orphan status, expedited programmes, or a PDUFA date. No review timeline can be reconstructed from them.

For cross-regional context, the records list the same substance in the EU as Celdoxome pegylated liposomal, with status Lapsed. The records do not link Celdoxome to Oxderys by company, formulation or development. No EU filing or CHMP opinion for Oxderys is recorded, and the CHMP opinion date is blank.

Safety and pharmacovigilance

The records contain no safety information for Oxderys. There are no labelled warnings, risk management measures, post-marketing commitments or adverse event data.

As with any newly approved US product, safety monitoring continues after approval through routine pharmacovigilance and the labelling. Whether additional measures such as a REMS or post-marketing requirements apply cannot be determined from these records. Professionals should read the approved label and the FDA approval documentation for the specifics.

What to watch

First, obtain the approved label and the FDA review documents to confirm the indication, strength, formulation type and any differences from existing doxorubicin products. These are the details missing from the records.

Second, check whether Avyxa Holdings has announced plans for the EU or other regions. The records show no such filing for Oxderys. The lapsed EU status of Celdoxome pegylated liposomal is a separate record and should not be assumed to relate to this product.

Third, watch for launch and supply information and for any post-approval labelling changes. The records do not cover these.